retatrutide phase 2 trial type 2 diabetes weight loss 🚨 BREAKING: Shows “Bariatric-Level” in 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most A New Obesity Drug Delivered

(And even if they were approved, pharmaceutical companies would shy away from them for fear of being undercut by compounding pharmacies.) If companies can sell them and make lots of money without having to prove that they do what theyre claimed to do, why wouldnt they? Zettler points out

We report that while SEMA led to substantial weight loss, reduced tumor engraftment, blunted progression, and reduced tumor burden compared to Veh, RETA demonstrated superior effectiveness with remarkable and sustained weight loss, profound reductions in tumor engraftment, and significantly reduced tumor burden compared to SEMA, WM-CR, and Veh

Retatrutide Retatrutide operates through triple receptor engagement targeting GLP-1, GIP, and glucagon receptors

10.1016/j.immuni.2021.11.015 30 OhtaM.MimoriK.FukuyoshiY.KitaY.MotoyamaK.YamashitaK.et al (2008)